Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immatics N.V.    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
Delayed Quote. Delayed Nasdaq - 01/15 04:00:01 pm
11.38 USD   -0.35%
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Immatics N.V.
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Number of employees : 227 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
T-Cell Redirecting Immunotherapies3.7784.8%18.4589.3% +389.36%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
Germany3.7784.8%18.4589.3% +389.36%
Managers and Directors
NameAgeSinceTitle
Harpreet Singh-Jasuja, Dr.462020Chief Executive Officer & Managing Director
Peter Alan Chambré642020Chairman-Supervisory Board
Arnd Christ532020Chief Financial Officer
Cedrik M. Britten, Dr.452020Chief Medical Officer
Steffen Walter, Dr.43-Chief Technology Officer
Michael G. Atieh662020Member-Supervisory Board
Paul R. Carter582020Member-Supervisory Board
Christof Hettich, Dr.612020Member-Supervisory Board
Heather L. Mason592020Member-Supervisory Board
Adam Stone402020Member-Supervisory Board
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,593,750 0 0.0% 0 0.0% 54.7%
Stock B 1 66,502,367 38,350,168 57.7% 0 0.0%
Shareholders
NameEquities%
dievini Hopp BioTech holding GmbH & Co. KG 16,476,073 26.2%
Arya Sciences Holdings 6,093,750 9.69%
Struengmann Family 4,911,778 7.81%
Wellington Partners GmbH 4,721,590 7.51%
Nantahala Capital Management LLC 2,622,164 4.17%
Perceptive Advisors LLC 2,500,000 3.97%
Redmile Group LLC 2,130,000 3.39%
Federated Global Investment Management Corp. 1,756,000 2.79%
Alyeska Investment Group LP 1,714,624 2.73%
683 Capital Management LLC 1,050,000 1.67%